1. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial;Eriksson;Journal of Thrombosis and Haemostasis,2005
2. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study;Colwell;Journal of Thrombosis and Haemostasis,2003
3. Randomized, double-blind, comparison of Ximelagatran, an oral direct thrombin iInhibitor, and Enoxaparin to prevent venous thromboembolism (VTE) after total hip arthroplasty (THA);Colwell;Blood,2001
4. Recombinant hirudin, desirudin (TMREVASC), is more effective than enoxaparin as prophylaxis of thromboembolic complications in patients undergoing total hip replacement;Eriksson;Thrombosis and Haemostasis,1997
5. Recombinant hirudin, CGP 39393, (TMREVASC), is more effective than enoxaparin as prophylaxis of thromboembolic complications in patients undergoing total hip replacement [Abstract];Eriksson;Journal of Bone and Joint Surgery British,1997